Literature DB >> 11297602

Decreased nocturnal levels of prolactin and growth hormone in women with fibromyalgia.

C A Landis1, M J Lentz, J Rothermel, S C Riffle, D Chapman, D Buchwald, J L Shaver.   

Abstract

Fibromyalgia (FM) is a complex syndrome, primarily of women, characterized by chronic pain, fatigue, and sleep disturbance. Altered function of the somatotropic axis has been documented in patients with FM, but little is known about nocturnal levels of PRL. As part of a laboratory study of sleep patterns in FM, we measured the serum concentrations of GH and PRL hourly from 2000--0700 h in a sample of 25 women with FM (mean, 46.9 +/- 7.6 yr) and in 21 control women (mean, 42.6 +/- 8.1 yr). The mean (+/-SEM ) serum concentrations (micrograms per L) of GH and of PRL during the early sleep period were higher in control women than in patients with FM [GH, 1.6 +/- 0.4 vs. 0.6 +/- 0.2 (P < 0.05); PRL, 23.2 +/- 2.2 vs. 16.9 +/- 2.0 (P < 0.025)]. The mean serum concentrations of GH and PRL increased more after sleep onset in control women than in patients with FM [GH, 1.3 +/- 0.4 vs. 0.3 +/- 0.2 (P < 0.05); PRL, 16.2 +/- 2.4 vs. 9.7 +/- 1.5 (P < 0.025)]. Sleep efficiency and amounts of sleep or wake stages on the blood draw night were not different between groups. There was a modest inverse relationship between sleep latency and PRL and a direct relationship between sleep efficiency and PRL in FM. There was an inverse relationship between age and GH most evident in control women. Insulin-like growth factor I levels were not different between the groups. These data demonstrate altered functioning of both the somatotropic and lactotropic axes during sleep in FM and support the hypothesis that dysregulated neuroendocrine systems during sleep may play a role in the pathophysiology of FM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297602     DOI: 10.1210/jcem.86.4.7427

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  [Fibromyalgia].

Authors:  M Späth
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

2.  Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome.

Authors:  Charles W Denko; Charles J Malemud
Journal:  Rheumatol Int       Date:  2004-07-24       Impact factor: 2.631

Review 3.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 4.  Neuroendocrine abnormalities in fibromyalgia.

Authors:  Gail K Adler; Valdis F Manfredsdottir; Katharine W Creskoff
Journal:  Curr Pain Headache Rep       Date:  2002-08

Review 5.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2005-10

6.  Growth hormone regulates the sensitization of developing peripheral nociceptors during cutaneous inflammation.

Authors:  Xiaohua Liu; Kathryn J Green; Zachary K Ford; Luis F Queme; Peilin Lu; Jessica L Ross; Frank B Lee; Aaron T Shank; Renita C Hudgins; Michael P Jankowski
Journal:  Pain       Date:  2017-02       Impact factor: 7.926

Review 7.  Fibromyalgia: symptom constellation and potential therapeutic options.

Authors:  Marjorie L Shuer
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

8.  The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial.

Authors:  Gerard K H The; Gijs Bleijenberg; Jos W M van der Meer
Journal:  PLoS Clin Trials       Date:  2007-05-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.